Biofrontera Résultats passés
Passé contrôle des critères 0/6
Biofrontera's earnings have been declining at an average annual rate of -7.5%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 13.8% per year.
Informations clés
-7.5%
Taux de croissance des bénéfices
51.5%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 6.0% |
| Taux de croissance des recettes | 13.8% |
| Rendement des fonds propres | -123.8% |
| Marge nette | -38.3% |
| Prochaine mise à jour des résultats | 13 Nov 2024 |
Mises à jour récentes des performances passées
Recent updates
Biofrontera Inc.'s (NASDAQ:BFRI) Shares Leap 25% Yet They're Still Not Telling The Full Story
Sep 28
Further Upside For Biofrontera Inc. (NASDAQ:BFRI) Shares Could Introduce Price Risks After 40% Bounce
Aug 09Take Care Before Jumping Onto Biofrontera Inc. (NASDAQ:BFRI) Even Though It's 29% Cheaper
May 24Biofrontera Inc. (NASDAQ:BFRI) Not Doing Enough For Some Investors As Its Shares Slump 28%
Dec 30The Market Doesn't Like What It Sees From Biofrontera Inc.'s (NASDAQ:BFRI) Revenues Yet As Shares Tumble 43%
Nov 13Can Biofrontera (NASDAQ:BFRI) Afford To Invest In Growth?
Oct 18Biofrontera announces preliminary Q3 product revenue, stock falls ~7% after hours
Oct 05Biofrontera gets notice of allowance for U.S. patent covering a nanoemulsion formulation
Sep 06Biofrontera GAAP EPS of -$0.05, revenue of $4.5M; reaffirms FY22 guidance
Aug 12Biofrontera announces 2Q prelim product revenues
Jul 12Ventilation des recettes et des dépenses
Comment Biofrontera gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Jun 24 | 35 | -14 | 35 | 1 |
| 31 Mar 24 | 33 | -23 | 38 | 0 |
| 31 Dec 23 | 34 | -20 | 38 | 0 |
| 30 Sep 23 | 34 | -26 | 38 | 0 |
| 30 Jun 23 | 29 | -23 | 38 | 0 |
| 31 Mar 23 | 28 | -14 | 36 | 0 |
| 31 Dec 22 | 29 | -1 | 35 | 0 |
| 30 Sep 22 | 28 | -12 | 24 | 0 |
| 30 Jun 22 | 28 | -26 | 33 | 0 |
| 31 Mar 22 | 29 | -29 | 29 | 0 |
| 31 Dec 21 | 24 | -38 | 26 | 0 |
| 30 Sep 21 | 24 | -23 | 32 | 0 |
| 30 Jun 21 | 22 | -10 | 19 | 0 |
| 31 Mar 21 | 19 | -10 | 17 | 0 |
| 31 Dec 20 | 19 | -11 | 18 | 0 |
| 31 Dec 19 | 26 | -11 | 28 | 0 |
Des revenus de qualité: BFRI is currently unprofitable.
Augmentation de la marge bénéficiaire: BFRI is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: BFRI is unprofitable, and losses have increased over the past 5 years at a rate of 7.5% per year.
Accélération de la croissance: Unable to compare BFRI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: BFRI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).
Rendement des fonds propres
ROE élevé: BFRI has a negative Return on Equity (-123.82%), as it is currently unprofitable.